Especially, for the in vivo use of DC/DCleu, the expression of the lymph-node-homing-receptor CCR7 (marker for mature DCs) is crucial for the migratory capacity of DCs and DCleu to the lymph node, where they activate T cells and other immunoreactive cells and induce anti-tumor/anti-leukemic activity [64,65,66]. This evidence concerns the gene CCR7 and neoplasm.